• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Concordbio Share Price

    Concord Biotech Share PriceConcord Biotech

    Mid Cap 2.1k Result
    ₹1,321.75
    -11.4 (-0.86%)
    As on 08 December, 2023 | 02:04 BSE: 543960 NSE: CONCORDBIOISIN: INE338H01029

    Concord Biotech Performance

    Day Range

    • Low 1,315.05
    • High 1,353.05
    ₹ 1,321.75

    52 Week Range

    • Low 900.05
    • High 1,397.05
    ₹ 1,321.75
    • Open Price1,345.65
    • Previous Close1,333.15
    • Volume69316

    Start SIP in Concord Biotech

    Start SIP

    Concord Biotech Share Price

    • Over 1 Month 10.16%
    • Over 3 Month 34.3%
    • Over 6 Month 78.37%
    • Over 1 Year 78.37%

    Concord Biotech Key Statistics

    P/E Ratio
    PEG Ratio
    Market Cap Cr 13,828
    Price to Book Ratio 10.7
    EPS 22.5
    Dividend 0
    Relative Strength Index 56.71
    Money Flow Index 62.97
    MACD Signal 36.63
    Average True Range 57.52

    Concord Biotech Investment Rating

    • Master Rating:

    • Concord Biotech Ltd has an operating revenue of Rs. 910.76 Cr. on a trailing 12-month basis. An annual revenue growth of 21% is outstanding, Pre-tax margin of 38% is great, ROE of 18% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 17% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 70 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 117 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Concord Biotech Financials
    IndicatorSep 2023Jun 2023
    Oper Rev Qtr Cr 262195
    Operating Expenses Qtr Cr 143123
    Operating Profit Qtr Cr 11972
    Depreciation Qtr Cr 1313
    Interest Qtr Cr 11
    Tax Qtr Cr 2917
    Net Profit Qtr Cr 8448
    IndicatorMar 2023
    Total Revenue Annual Cr 888
    Operating Expenses Annual Cr 510
    Operating Profit Annual in Cr 343
    Depreciation Cr 54
    Interest Annual Cr 5
    Tax Annual Cr 82
    Net Profit Annual Cr 238
    IndicatorMar 2023
    Cash from Operating Activity Annual Cr 246
    Cash from Investing Activity Annual Cr -158
    Cash from Financing Annual Activity Cr -85
    Net Cash Flow Annual Cr 3
    IndicatorMar 2023
    Total ShareHolders Funds Annual Cr 1,292
    Fixed Assets Annual Cr 766
    Total Non Current Assets Annual Cr 787
    Total Current Assets Annual Cr 728
    Total Assets Annual Cr 1,515
    IndicatorMar 2023
    Book Value Per Share Annual Rs 123
    ROE Annual % 18
    ROCE Annual % 25
    Total Debt to Total Equity Annual -
    EBDIT Annual Margin % 44
    IndicatorSep 2023Jun 2023
    Oper Rev Qtr Cr 262195
    Operating Expenses Qtr Cr 143123
    Operating Profit Qtr Cr 11972
    Depreciation Qtr Cr 1313
    Interest Qtr Cr 11
    Tax Qtr Cr 2917
    Net Profit Qtr Cr 8154
    IndicatorMar 2023
    Total Revenue Annual Cr 888
    Operating Expenses Annual Cr 510
    Operating Profit Annual in Cr 343
    Depreciation Cr 54
    Interest Annual Cr 5
    Tax Annual Cr 82
    Net Profit Annual Cr 240
    IndicatorMar 2023
    Cash from Operating Activity Annual Cr 246
    Cash from Investing Activity Annual Cr -158
    Cash from Financing Annual Activity Cr -85
    Net Cash Flow Annual Cr 3
    IndicatorMar 2023
    Total ShareHolders Funds Annual Cr 1,290
    Fixed Assets Annual Cr 766
    Total Non Current Assets Annual Cr 786
    Total Current Assets Annual Cr 728
    Total Assets Annual Cr 1,514
    IndicatorMar 2023
    Book Value Per Share Annual Rs 123
    ROE Annual % 19
    ROCE Annual % 25
    Total Debt to Total Equity Annual -
    EBDIT Annual Margin % 44
    Invest in Concord Biotech

    Concord Biotech Technicals

    EMA & SMA

    Current Price
    ₹1,321.75
    -11.4 (-0.86%)
    pointer
    • Bullish Moving Average
    • ___
    • 9
    • Bearish Moving Average
    • ___
    • 2
    • 20 Day
    • ₹1,289.47
    • 50 Day
    • ₹1,205.64
    • 100 Day
    • ₹
    • 200 Day
    • ₹
    • 20 Day
    • ₹1,305.21
    • 50 Day
    • ₹1,206.90
    • 100 Day
    • ₹
    • 200 Day
    • ₹

    Concord Biotech Resistance and Support

    PIVOT
    ₹1,329.95
    Resistance
    First Resistance 1,344.85
    Second Resistance 1,367.95
    Third Resistance 1,382.85
    RSI 56.71
    MFI 62.97
    MACD Single Line 36.63
    MACD 35.73
    Support
    First Resistance 1,306.85
    Second Resistance 1,291.95
    Third Resistance 1,268.85

    Concord Biotech Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 73,941 3,526,246 47.69
    Week 133,650 5,984,829 44.78
    1 Month 322,867 15,029,481 46.55
    6 Month 408,323 17,990,696 44.06

    Concord Biotech Result Highlights

    Concord Biotech Synopsis

    NSE-Medical-Biomed/Biotech

    Concord Biotech Ltd. is involved in the business activities of Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 853.17 Cr. and Equity Capital is Rs. 10.46 Cr. for the Year ended 31/03/2023. Concord Biotech Ltd. is a Public Limited Listed company incorporated on 23/11/1984 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is U24230GJ1984PLC007440 and registration number is 007440.
    Market Cap 13,862
    Sales 1,310
    Shares in Float 5.86
    No of funds 60
    Yield
    Book Value 10.73
    U/D Vol ratio 1.7
    LTDebt / Equity 3
    Alpha 0.41
    Beta 0.86

    Concord Biotech

    Owner NameSep-23
    Promoters 44.08%
    Mutual Funds 5.58%
    Insurance Companies 2.26%
    Foreign Portfolio Investors 7.3%
    Individual Investors 6.78%
    Others 34%

    Concord Biotech Management

    Name Designation
    Mr. Sudhir Vaid Chairman & Managing Director
    Mr. Ankur Vaid Joint Managing Director & CEO
    Mr. Ravi Kapoor Non Executive Director
    Mr. Rajiv Ambrish Agarwal Non Exe. & Nominee Director
    Mr. Utpal Sheth Non Exe. & Nominee Director
    Mr. Amit Varma Non Exe. & Nominee Director
    Ms. Bharti Khanna Independent Director
    Mr. Anil Katyal Independent Director
    Mr. Amitabh Thakore Independent Director
    Mr. Arvind Agarwal Independent Director
    Mr. Jayaram Easwaran Independent Director
    Mr. Mandayam Chakravarthy Sriraman Independent Director

    Concord Biotech Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Concord Biotech Corporate Action

    Date Purpose Remarks
    2023-11-08 Quarterly Results

    Concord Biotech MF Shareholding

    Name Amount(cr)
    Nippon India Small Cap Fund - Growth 37,319
    HSBC Small Cap Fund Fund Regular Growth 11,552
    Franklin India Smaller Companies Fund Growth 9,684
    Edelweiss Balanced Advantage Fund Regular Plan Growth 9,338
    Nippon India Pharma Fund - Growth 5,539

    Concord Biotech FAQs

    What is Share Price of Concord Biotech ?

    Concord Biotech share price is ₹1,321 As on 08 December, 2023 | 01:50

    What is the Market Cap of Concord Biotech ?

    The Market Cap of Concord Biotech is ₹13827.6 Cr As on 08 December, 2023 | 01:50

    What is the P/E ratio of Concord Biotech ?

    The P/E ratio of Concord Biotech is As on 08 December, 2023 | 01:50

    What is the PB ratio of Concord Biotech ?

    The PB ratio of Concord Biotech is 10.7 As on 08 December, 2023 | 01:50

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.